- Home
- VTYX vs ACRS Comparison
VTYX vs ACRS Comparison
Compare VTYX & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- ACRS
- Stock Information
- Founded
- VTYX 2018
- ACRS 2012
- Country
- VTYX United States
- ACRS United States
- Employees
- VTYX N/A
- ACRS N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- VTYX Health Care
- ACRS Health Care
- Exchange
- VTYX Nasdaq
- ACRS Nasdaq
- Market Cap
- VTYX 154.9M
- ACRS 165.7M
- IPO Year
- VTYX 2021
- ACRS 2015
- Fundamental
- Price
- VTYX $2.79
- ACRS $1.59
- Analyst Decision
- VTYX Buy
- ACRS Strong Buy
- Analyst Count
- VTYX 4
- ACRS 9
- Target Price
- VTYX $11.33
- ACRS $9.25
- AVG Volume (30 Days)
- VTYX 2.0M
- ACRS 1.3M
- Earning Date
- VTYX 08-07-2025
- ACRS 08-06-2025
- Dividend Yield
- VTYX N/A
- ACRS N/A
- EPS Growth
- VTYX N/A
- ACRS N/A
- EPS
- VTYX N/A
- ACRS N/A
- Revenue
- VTYX N/A
- ACRS $17,777,000.00
- Revenue This Year
- VTYX N/A
- ACRS N/A
- Revenue Next Year
- VTYX N/A
- ACRS $11.77
- P/E Ratio
- VTYX N/A
- ACRS N/A
- Revenue Growth
- VTYX N/A
- ACRS N/A
- 52 Week Low
- VTYX $0.78
- ACRS $1.05
- 52 Week High
- VTYX $3.39
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- VTYX 62.76
- ACRS 59.88
- Support Level
- VTYX $1.95
- ACRS $1.44
- Resistance Level
- VTYX $2.51
- ACRS $1.52
- Average True Range (ATR)
- VTYX 0.17
- ACRS 0.10
- MACD
- VTYX -0.02
- ACRS 0.00
- Stochastic Oscillator
- VTYX 104.37
- ACRS 79.17
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.